Funder: Breakthrough T1D

Due Dates: October 29, 2025 (Letter of Intent) | January 13, 2026 (Full proposal)

Funding Amounts: Up to $3,000,000 total for up to 3 years; typical awards may be smaller depending on scope.

Summary: Supports clinical trials to advance therapies improving cardiovascular outcomes in people with type 1 diabetes.

Key Information: LOI is required; academic and industry applicants eligible; strong emphasis on innovation and T1D-specific impact.